SARS-CoV-2 Membrane-, Envelope-, Nucleoprotein Protein
Origin: SARS Coronavirus-2 (SARS-CoV-2)
Host: HEK-293 Cells
cVLP
ELISA, NTA, WB
-
- Target
- SARS-CoV-2 Membrane-, Envelope-, Nucleoprotein
- Protein Type
- cVLP
- Origin
- SARS Coronavirus-2 (SARS-CoV-2)
-
Source
- HEK-293 Cells
- Application
- ELISA, Nanoparticle Tracking Analysis (NTA), Western Blotting (WB)
- Purpose
- Chimeric VLP of SARS-CoV-2 (M+E+N) can be used as a control
- Characteristics
- Chimeric SARS-CoV-2 virus-like particles (cVLP) were produced in HEK cells by co-expression of the membrane-, envelope- and nucleoprotein with a membrane bound target protein. The VLPs do not contain the viral genome, cannot replicate and are not infectious.
- Purification
- Polyethylene glycol precipitation
- Biological Activity Comment
- active
-
-
- Application Notes
-
Applications: Immunogenic antigen, antigen for ELISA and Western blot.
Western blot: 1-10 μg, ELISA: 1-5 μg/mL - Comment
-
Virus-like Particles are multiprotein complexes that resemble a native virus, but lack the genetic information. Therefore, VLPs are safe to handle in numerous fields of applications. For example, VLPs can be applied as antigen in serological assays (e.g. ELISA), or serve as reference material to standardize the performance of different diagnostic tests (e.g. rapid antigen tests or ELISA). Due to the self-adjuvanting properties of VLPs is the most common application of VLPs the use as antigen for immunizations for vaccine development or antibody discovery campaigns.
- Restrictions
- For Research Use only
-
- Format
- Liquid
- Concentration
- Lot specific
- Buffer
- PBS
- Storage
- -80 °C
- Storage Comment
- - 80°C
-
- Target
- SARS-CoV-2 Membrane-, Envelope-, Nucleoprotein
- Background
- SARS-CoV-2 (Severe acute respiratory syndrome coronavirus type 2) is a coronavirus (genus: Betacoronavirus, subgenus: Sarbecovirus) that was identified as the cause of COVID-19 disease in early 2020.
-
You are here:
